Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buscopan + Brufen crossover study in primary dysmenorrhea
2019-004138-41Phase 4Terminated
- Sponsor
- Sanofi
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of hyoscine butylbromide and ibuprofen in primary dysmenorrhea (PD) (6 arms), sponsored by Sanofi. Primary endpoint: Pain Intensity. Started May 2020; status: terminated.
02
Drugs
hyoscine butylbromideibuprofen
03
Conditions
primary dysmenorrhea (PD)
Beyond the preview
Go deeper on 2019-004138-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004138-41.